BACKGROUND AND PURPOSE Faciobrachial dystonic seizures (FBDS) and hyponatraemia are the distinct clinical features of autoimmune encephalitis (AE) caused by antibodies against leucine-rich glioma-inactivated 1 (LGI1). The pathophysiological pattern and… Click to show full abstract
BACKGROUND AND PURPOSE Faciobrachial dystonic seizures (FBDS) and hyponatraemia are the distinct clinical features of autoimmune encephalitis (AE) caused by antibodies against leucine-rich glioma-inactivated 1 (LGI1). The pathophysiological pattern and neural mechanisms underlying these symptoms remain largely unexplored. METHODS We included 30 patients with anti-LGI1 AE and 30 controls from a retrospective observational cohort. Whole-brain metabolic pattern analysis was performed to assess the pathological network of anti-LGI1 AE, as well as the symptomatic networks of FBDS. Logistic regression was applied to explore independent predictors of FBDS. Finally, we applied multiple regression model to investigate the hyponatraemia-associated brain network and its effect on serum sodium levels. RESULTS The pathological network of anti-LGI1 AE involved a hypermetabolism in cerebellum, subcortical structures, and Rolandic area, as well as a hypometabolism in the medial prefrontal cortex. The symptomatic network of FBDS shown a hypometabolism in cerebellum and Rolandic area (PFDR < 0.05). Hypometabolism in the cerebellum was an independent predictor of FBDS (P < 0.001). Hyponatraemia-associated network highlighted a negative effect on caudate nucleus, frontal and temporal white matter. Serum sodium level had the negative trend with metabolism of hypothalamus (Pearson's R = -0.180, P = 0.342) but the mediation was not detected (path c' = -7.238, 95% CI = -30.947 to 16.472). CONCLUSIONS Our results provide insights into the whole-brain metabolic patterns of patients with anti-LGI1 AE, including the symptomatic network FBDS and the hyponatraemia-associated brain network, which is conducive to understanding the neural mechanisms and evaluating disease progress of anti-LGI1 AE.
               
Click one of the above tabs to view related content.